CancerIQ, a leading precision health platform specializing in cancer prevention and early detection, has secured a growth funding package from Decathlon Capital Partners. Although financial details were not disclosed, the funding will support CancerIQ's ongoing platform development, the introduction of new offerings, and the expansion of partnerships with health systems and hospitals. CancerIQ’s platform integrates into electronic health record (EHR) workflows, allowing providers to identify patients' hereditary cancer risks and personalize care plans based on the latest guidelines.
Co-Founder and CEO Feyi Olopade Ayodele emphasized the platform's ability to deliver tailored care for cancer prevention, early detection, and treatment. This patient-centered approach sets CancerIQ apart from its competitors by moving away from a one-size-fits-all model. Ben Bowman, the company's CFO, noted that the funding structure allows CancerIQ to repay the investment through future revenues without sacrificing equity or control, making it a financially sustainable growth strategy.
John Borchers, Managing Director at Decathlon Capital Partners, praised CancerIQ's dual benefits for patients and providers, highlighting how the platform not only improves patient care but also aids healthcare providers in managing their operations effectively. CancerIQ's innovative approach, recognized by industry leaders, continues to make strides in transforming cancer care and expanding access to personalized, evidence-based treatment plans.
Click here to read the original news story.